• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

TERAZOSIN Drug Record

  • Summary
  • Interactions
  • Claims
  • TERAZOSIN chembl:CHEMBL611 ApprovedAntineoplastic

    Alternate Names:

    TERAZOSIN
    HYTRIN
    TÉRAZOSINE
    HYTRIN®
    ABBOTT-45975
    1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((TETRAHYDRO-2-FURANYL)CARBONYL)PIPERAZINE
    TERAZOSINUM
    TERAZOSINA
    TERAZOSINE
    rxcui:37798
    chemidplus:63590-64-7
    drugbank:01162
    chembl:CHEMBL611
    pubchem.compound:5401

    Drug Info:

    FDA Approval 1987
    Drug Class small molecule
    Drug Indications antihypertensive agents
    Drug Indications Antineoplastic Agents
    Drug Class antineoplastic agents
    Year of Approval 1987
    Drug Class antihypertensive agents
    (2 More Sources)

    Publications:

    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Michel et al., 1996, Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate., J Auton Pharmacol
    Lee et al., 1997, Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses., Br J Urol
    Na et al., 1998, Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group., J Med
    Roehrborn et al., 2004, Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia., J. Urol.
    Chapple, 1998, Medical therapy and quality of life., Eur. Urol.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Simpson, 1985, Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating., Circ. Res.
    Vincent et al., 1992, Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans., J. Clin. Invest.
    Boyle et al., 2001, Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia., Urology
  • TERAZOSIN   ADRA1D

    Interaction Score: 0.95

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • TERAZOSIN   ADRA1B

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2988814 1358918 11711348 11752352


    Sources:
    TdgClinicalTrial TEND

  • TERAZOSIN   ADRA1A

    Interaction Score: 0.57

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8736427 9352700 10503165 14767264 9732824 11752352


    Sources:
    TdgClinicalTrial TEND

  • TERAZOSIN   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • TERAZOSIN   HTT

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TERAZOSIN   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TERAZOSIN   CYP2C19

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TERAZOSIN   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TERAZOSIN   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TERAZOSIN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: TERAZOSIN

    • Version: 01-August-2011

    Alternate Names:
    TERAZOSIN Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1987
    Drug Class antineoplastic agents

    Publications:

  • TdgClinicalTrial: TERAZOSIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Indications antihypertensive agents
    Drug Class small molecule

    Publications:

  • DTC: TERAZOSIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL611 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: terazosin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

  • TTD: Terazosin

    • Version: 2020.06.01

    Alternate Names:
    D0P9RF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL611

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21